GlassScriptPhysician profile
Fredrick Allen May
NPI 1659557007
$102,197.54
in general payments reported to CMS, 2019-2025
27 companies · $20K in 2025
The $20K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $11K · 2021: $9,502 · 2022: $13K · 2023: $547 · 2024: $375 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $1,547 · Food and Beverage: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,259.00 |
| Travel and Lodging | $1,546.77 |
| Food and Beverage | $286.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $11,693.93 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $9,709.59 | 2025 | Zilretta, Exparel |
| Sight Sciences, INC. | $9,450.00 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,310.90 | 2025 | |
| Celgene Corporation | $6,790.81 | 2019 | |
| Genzyme Corporation | $6,462.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $4,717.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $4,513.80 | 2019 | |
| Pfizer INC. | $4,440.00 | 2022 | |
| Osiris Therapeutics INC. | $4,236.98 | 2019 | |
| Blue Earth Diagnostics | $3,691.45 | 2019 | |
| Bioventus LLC | $3,593.11 | 2019 | |
| Eisai INC. | $3,380.00 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $3,284.24 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $3,150.00 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $2,807.36 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $2,325.00 | 2022-2024 | |
| Kyowa Kirin, INC. | $2,202.07 | 2019 | |
| Janssen Pharmaceuticals, INC | $1,950.00 | 2020 | |
| Astellas Pharma Global Development | $1,640.00 | 2021 | |
| Novo Nordisk As | $1,440.00 | 2022 | |
| Astrazeneca Uk Limited | $1,024.00 | 2019 | |
| Gilead Sciences, INC. | $787.50 | 2019 | |
| Ge Healthcare | $631.90 | 2022-2023 | |
| Csl Behring | $568.75 | 2020 | |
| Therapeuticsmd, INC. | $300.00 | 2019 | |
| Vertos Medical, INC. | $96.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredrick May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.